

Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

AMARIN CORP PLC\UK
Form 6-K
March 15, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934

March 15, 2005

Commission File Number 0-21392

AMARIN CORPORATION PLC
(Translation of registrant's name into English)

7 Curzon Street
London W1J 5HG
England
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F []

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [] No

Attachment:

Material Events

(a) Amarin Corporation announces positive clinical data for Miraxion(TM) to treat unresponsive depression.

This report on Form 6-K is hereby incorporated by reference in (a) the registration statement on Form F-3 (Registration No. 333-104748) of Amarin Corporation plc and in the prospectus contained therein, (b) the registration statement on Form F-3 (Registration No. 333-13200) of Amarin Corporation plc and in the prospectus contained therein, (c) the registration statement on Form F-3 (Registration No. 333-12642) of Amarin Corporation plc and in the prospectus contained therein, (d) the registration statement on Form F-3 (Registration No. 333-121431) of Amarin Corporation plc and in the prospectus contained therein and (e) the registration statement on Form F-3 (Registration No. 333-121760) of Amarin Corporation plc and in the prospectus contained therein,, and this report on Form 6-K shall be deemed a part of each such registration statement from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished by Amarin

Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

Corporation plc under the Securities Act of 1933 or the Securities Exchange Act of 1934.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMARIN CORPORATION PLC

By: /s/ JONATHAN LAMB

Name: Jonathan Lamb

Title: Secretary

Date: March 15, 2005

EXHIBIT INDEX

Index to Exhibits

Exhibit Item	Sequentially Numbered Page
(a) Material event description	4

Contact:

Rick Stewart
Chief Executive Officer
Amarin Corporation plc
Phone: +44 (0) 207 907 2442
investor.relations@amarincorp.com

Alan Cooke
Chief Financial Officer
Amarin Corporation plc
Phone: +44 (0) 207 907 2442
investor.relations@amarincorp.com

AMARIN CORPORATION ANNOUNCES ADDITIONAL POSITIVE CLINICAL DATA FOR MIRAXION(TM) TO TREAT UNRESPONSIVE DEPRESSION

-- Consistent data in three Phase IIa clinical trials in depression patients with melancholic characteristics --

LONDON, United Kingdom, March 15, 2005 - Amarin Corporation plc (NASDAQSC: AMRN) today announced positive data analysis from a third exploratory phase IIa clinical trial using Miraxion to treat depression. Miraxion was used

Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

as adjunct therapy (with either SSRI's or tricyclics) in 115 patients with treatment-unresponsive depression in a 12-week double blind, placebo controlled clinical trial. The Hamilton Depression Rating Scale (HDRS) was used as the primary efficacy measure. Although in the whole group Miraxion did not show a significant difference over placebo, an exploratory analysis demonstrated significant superiority ($p < 0.05$) in the subgroup of depression patients ($n = 70$) with melancholic characteristics using a repeated measurements design.

This sub-group of depression patients was defined by using select criteria from DSM-IV (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition) which is the main diagnostic reference of Mental Health professionals in the United States of America, published by the American Psychiatric Association, Washington D.C. Identical methodology was used to identify melancholic depression patients in the previously announced data analysis from the 77 patient monotherapy trial and the 70 patient adjunct therapy depression trial. The data from all three trials are consistent and show a significant clinical benefit using Miraxion in patients with depression with melancholic characteristics.

On 12th January 2005, Amarin announced data from a monotherapy clinical trial using Miraxion alone to treat depression patients. The monotherapy trial included 77 patients, of whom 39 patients were identified with melancholic depression characteristics. In this group, statistical significance ($p =$